1. Home
  2. ADVB vs STTK Comparison

ADVB vs STTK Comparison

Compare ADVB & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVB
  • STTK
  • Stock Information
  • Founded
  • ADVB 2014
  • STTK 2016
  • Country
  • ADVB United States
  • STTK United States
  • Employees
  • ADVB N/A
  • STTK N/A
  • Industry
  • ADVB Medical Specialities
  • STTK Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVB Health Care
  • STTK Health Care
  • Exchange
  • ADVB Nasdaq
  • STTK Nasdaq
  • Market Cap
  • ADVB 36.1M
  • STTK 37.6M
  • IPO Year
  • ADVB 2025
  • STTK 2020
  • Fundamental
  • Price
  • ADVB $0.95
  • STTK $0.95
  • Analyst Decision
  • ADVB
  • STTK Hold
  • Analyst Count
  • ADVB 0
  • STTK 4
  • Target Price
  • ADVB N/A
  • STTK $3.00
  • AVG Volume (30 Days)
  • ADVB 182.8K
  • STTK 115.8K
  • Earning Date
  • ADVB 01-01-0001
  • STTK 05-01-2025
  • Dividend Yield
  • ADVB N/A
  • STTK N/A
  • EPS Growth
  • ADVB N/A
  • STTK N/A
  • EPS
  • ADVB N/A
  • STTK N/A
  • Revenue
  • ADVB N/A
  • STTK $4,606,000.00
  • Revenue This Year
  • ADVB N/A
  • STTK N/A
  • Revenue Next Year
  • ADVB N/A
  • STTK N/A
  • P/E Ratio
  • ADVB N/A
  • STTK N/A
  • Revenue Growth
  • ADVB N/A
  • STTK 69.65
  • 52 Week Low
  • ADVB $1.01
  • STTK $0.69
  • 52 Week High
  • ADVB $4.10
  • STTK $11.76
  • Technical
  • Relative Strength Index (RSI)
  • ADVB N/A
  • STTK 50.37
  • Support Level
  • ADVB N/A
  • STTK $0.84
  • Resistance Level
  • ADVB N/A
  • STTK $1.12
  • Average True Range (ATR)
  • ADVB 0.00
  • STTK 0.10
  • MACD
  • ADVB 0.00
  • STTK 0.02
  • Stochastic Oscillator
  • ADVB 0.00
  • STTK 53.84

About ADVB Advanced Biomed Inc. Common Stock

Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: